12/22
07:26 pm
gpcr
Structure Therapeutics (GPCR) valuation check after Phase 1 obesity candidate ACCG-2671 enters first-in-human trial [Yahoo! Finance]
High
Report
Structure Therapeutics (GPCR) valuation check after Phase 1 obesity candidate ACCG-2671 enters first-in-human trial [Yahoo! Finance]
12/19
09:09 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/17
08:40 am
gpcr
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]
Low
Report
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]
12/17
08:30 am
gpcr
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Low
Report
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
12/13
01:10 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at
Wall St
Medium
Report
Structure Therapeutics (NASDAQ:GPCR) was upgraded by analysts at
Wall St
12/12
10:02 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
12/12
08:06 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its price target raised by analysts at Citizens Jmp from $87.00 to $120.00. They now have a "market outperform" rating on the stock.
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its price target raised by analysts at Citizens Jmp from $87.00 to $120.00. They now have a "market outperform" rating on the stock.
12/12
07:12 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
12/11
04:14 pm
gpcr
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs [Yahoo! Finance]
Low
Report
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs [Yahoo! Finance]
12/11
04:01 pm
gpcr
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs
Low
Report
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs
12/11
12:01 pm
gpcr
Structure Therapeutics (NASDAQ:GPCR) was given a new $125.00 price target on by analysts at Jefferies Financial Group Inc..
Low
Report
Structure Therapeutics (NASDAQ:GPCR) was given a new $125.00 price target on by analysts at Jefferies Financial Group Inc..
12/10
12:10 am
gpcr
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants [Yahoo! Finance]
Medium
Report
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants [Yahoo! Finance]
12/9
11:15 pm
gpcr
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
Medium
Report
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
12/9
09:37 pm
gpcr
Structure Therapeutics (GPCR) Is Up 121.3% After Strong Phase 2b Data For Oral GLP-1 Aleniglipron - What's Changed [Yahoo! Finance]
Medium
Report
Structure Therapeutics (GPCR) Is Up 121.3% After Strong Phase 2b Data For Oral GLP-1 Aleniglipron - What's Changed [Yahoo! Finance]
12/9
07:01 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
12/8
06:06 pm
gpcr
Structure Therapeutics (NASDAQ:GPCR) was given a new $90.00 price target on by analysts at Stifel Nicolaus.
Medium
Report
Structure Therapeutics (NASDAQ:GPCR) was given a new $90.00 price target on by analysts at Stifel Nicolaus.
12/8
04:02 pm
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
12/8
04:01 pm
gpcr
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants
Low
Report
Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants
12/8
08:00 am
gpcr
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
High
Report
Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
12/7
06:20 pm
gpcr
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
High
Report
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
12/2
01:05 pm
gpcr
Structure Therapeutics (NASDAQ:GPCR) was given a new $50.00 price target on by analysts at Stifel Nicolaus.
Medium
Report
Structure Therapeutics (NASDAQ:GPCR) was given a new $50.00 price target on by analysts at Stifel Nicolaus.
11/28
07:02 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/24
07:02 am
gpcr
Structure Therapeutics (NASDAQ:GPCR) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Structure Therapeutics (NASDAQ:GPCR) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/16
10:26 pm
gpcr
BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts [Yahoo! Finance]
Low
Report
BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts [Yahoo! Finance]
11/6
04:01 pm
gpcr
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Low
Report
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights